CheckMate 153
NCT02066636
JCP005
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)
Status:
Closed to Accrual
III
Phase
1st
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
EGFR
Investigational
Product
Nivolumab
Anti-PD-1 Monoclonal Antibody (i.v.)
Treatment Arms
o Experimental with 2 cohorts